Trials / Completed
CompletedNCT02651714
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tradipitant | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-01-19
- Primary completion
- 2017-08-04
- Completion
- 2017-08-04
- First posted
- 2016-01-11
- Last updated
- 2024-06-13
- Results posted
- 2024-06-13
Locations
28 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02651714. Inclusion in this directory is not an endorsement.